{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:53Z","timestamp":1740108293521,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00198-022-06618-1","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:46:07Z","timestamp":1669902367000},"page":"423-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia"],"prefix":"10.1007","volume":"34","author":[{"given":"C.","family":"Crotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0909","authenticated-orcid":false,"given":"M.","family":"Varenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"4","key":"6618_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36(4):627\u2013635. https:\/\/doi.org\/10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"issue":"2","key":"6618_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S (2021) Interim analysis of a phase 2 open-label trial assessing Burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36(2):262\u2013270. https:\/\/doi.org\/10.1002\/jbmr.4184","journal-title":"J Bone Miner Res"},{"key":"6618_CR3","doi-asserted-by":"publisher","first-page":"116077","DOI":"10.1016\/j.bone.2021.116077","volume":"152","author":"C Crotti","year":"2021","unstructured":"Crotti C, Bartoli F, Coletto LA, Manara M, Marini E, Daolio PA, Parafioriti A, Armiraglio E, Zucchi F, Sinigaglia L, Caporali R, Varenna M (2021) Tumor induced osteomalacia: a single center experience on 17 patients. Bone 152:116077. https:\/\/doi.org\/10.1016\/j.bone.2021.116077","journal-title":"Bone"},{"issue":"7","key":"6618_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/jbmr.3417","volume":"33","author":"L Xiao","year":"2018","unstructured":"Xiao L, Homer-Bouthiette C, Hurley MM (2018) FGF23 neutralizing antibody partially improves bone mineralization defect of HMWFGF2 isoforms in transgenic female mice. J Bone Miner Res 33(7):1347\u20131361. https:\/\/doi.org\/10.1002\/jbmr.3417","journal-title":"J Bone Miner Res"},{"issue":"1","key":"6618_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5414\/CN108596","volume":"85","author":"S Bansal","year":"2016","unstructured":"Bansal S, Khazim K, Suri R, Martin D, Werner S, Fanti P (2016) Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23. Clin Nephrol 85(1):57\u201362. https:\/\/doi.org\/10.5414\/CN108596","journal-title":"Clin Nephrol"},{"issue":"8","key":"6618_CR6","first-page":"9422","volume":"8","author":"S Tajima","year":"2015","unstructured":"Tajima S, Fukayama M (2015) Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors. Int J Clin Exp Pathol 8(8):9422\u20139427","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"6618_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/ckj\/sfu004","volume":"7","author":"A Amblee","year":"2014","unstructured":"Amblee A, Uy J, Senseng C, Hart P (2014) Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level. Clin Kidney J 7(2):186\u2013189. https:\/\/doi.org\/10.1093\/ckj\/sfu004","journal-title":"Clin Kidney J"},{"issue":"5","key":"6618_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/modpathol.3800084","volume":"17","author":"S Toyosawa","year":"2004","unstructured":"Toyosawa S, Tomita Y, Kishino M, Hashimoto J, Ueda T, Tsujimura T, Aozasa K, Ijuhin N, Komori T (2004) Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia. Mod Pathol 17(5):573\u2013578. https:\/\/doi.org\/10.1038\/modpathol.3800084","journal-title":"Mod Pathol"},{"issue":"1","key":"6618_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1006\/geno.2000.6235","volume":"67","author":"PS Rowe","year":"2000","unstructured":"Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67(1):54\u201368. https:\/\/doi.org\/10.1006\/geno.2000.6235","journal-title":"Genomics"},{"key":"6618_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06516-6","author":"C Crotti","year":"2022","unstructured":"Crotti C, Zucchi F, Alfieri C, Caporali R, Varenna M (2022) Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-022-06516-6","journal-title":"Osteoporos Int"},{"issue":"4","key":"6618_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L (2017) Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31(4):299\u2013316. https:\/\/doi.org\/10.1007\/s40259-017-0231-8","journal-title":"BioDrugs"},{"issue":"6","key":"6618_CR12","doi-asserted-by":"publisher","first-page":"e0179308","DOI":"10.1371\/journal.pone.0179308","volume":"12","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B (2017) Correction: the impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. Plos One 12(6):e0179308. https:\/\/doi.org\/10.1371\/journal.pone.0179308","journal-title":"Plos One"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06618-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:46:37Z","timestamp":1674495997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06618-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6618"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06618-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Massimo Varenna has received advisory board honoraria from Kyowa Kirin. Chiara Crotti has received speaker honoraria from Kyowa Kirin. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}